The P-Glycoprotein Antagonist PSC 833 Increases the Plasma Concentrations of 6 a-Hydroxypaclitaxel , a Major Metabolite of Paclitaxel 1


Purpose: Overexpression of P-glycoprotein (Pgp) is one mechanism of drug resistance in cancer chemotherapy. A Phase I trial was conducted using PSC 833, a Pgp antagonist, in combination with paclitaxel in patients with refractory cancer. The objective of this study was to assess the effect of PSC 833 on the metabolism of paclitaxel and characterize the… (More)

9 Figures and Tables


  • Presentations referencing similar topics